Treatment Perspective of RAS Testing Implementation in Colorectal Cancer

Speaker: Jean-Yves Douillard

J-Y. Douillard describes a shift from KRAS towards broader RAS testing in colorectal cancer due to results of clinical studies that supported this change in clinical practice. He details the mutations within the RAS family and their consequences for medical treatment selection in focused patient populations.

Discussion Points

  • RAS mutation status as an important biomarker to select treatment for patients with metastatic colorectal cancer;
  • Clinical importance of the shift from KRAS to RAS testing;
  • Results of clinical studies that led to change in practice;
  • Clinical practice considerations for RAS testing